Ozagrel (BioDeep_00000399077)

   

natural product


代谢物信息卡片


3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2E-propenoic acid

化学式: C13H12N2O2 (228.0898732)
中文名称: 奥扎格雷
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=C(C=CC(=C1)/C=C/C(O)=O)CN2C=NC=C2
InChI: InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

描述信息

D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents
D050299 - Fibrin Modulating Agents
D002317 - Cardiovascular Agents
D004791 - Enzyme Inhibitors
C471 - Enzyme Inhibitor

同义名列表

2 个代谢物同义名

Ozagrel; 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2E-propenoic acid



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Xiaoan Li, Tiantian Guo, Qian Feng, Tiantian Bai, Lei Wu, Yubo Liu, Xu Zheng, Jianzhong Jia, Jin Pei, Shaoping Wu, Yiming Song, Yongmin Zhang. Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs. European journal of medicinal chemistry. 2022 Jan; 228(?):114035. doi: 10.1016/j.ejmech.2021.114035. [PMID: 34902735]
  • Pankaj Bhatia, Nirmal Singh. Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. Fundamental & clinical pharmacology. 2021 Aug; 35(4):650-666. doi: 10.1111/fcp.12610. [PMID: 33020931]
  • Pankaj Bhatia, Gagandeep Kaur, Nirmal Singh. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. Vascular pharmacology. 2021 04; 137(?):106827. doi: 10.1016/j.vph.2020.106827. [PMID: 33346090]
  • Kai-Jing Zhao, Yang Chen, Shi-Jin Hong, Yi-Ting Yang, Jiong Xu, Han-Yu Yang, Liang Zhu, Ming Liu, Qiu-Shi Xie, Xian-Ge Tang, Ting-Ting Yang, Ya-Qian Zhou, Li Liu, Xiao-Dong Liu. Characteristics of β-oxidative and reductive metabolism on the acyl side chain of cinnamic acid and its analogues in rats. Acta pharmacologica Sinica. 2019 Aug; 40(8):1106-1118. doi: 10.1038/s41401-019-0218-8. [PMID: 30792487]
  • Zhi-Zhen Qin, Qian-Xi Chen, Jun-Ke Song, Yang Lü, Guan-Hua Du. [Pharmacokinetic comparison of two ozagrel polymorph forms in SD rats]. Yao xue xue bao = Acta pharmaceutica Sinica. 2015 Feb; 50(2):218-21. doi: NULL. [PMID: 25975032]
  • Yoshiro Tomishima, Yoichi Ishitsuka, Naoya Matsunaga, Minako Nagatome, Hirokazu Furusho, Mitsuru Irikura, Shigehiro Ohdo, Tetsumi Irie. Ozagrel hydrochloride, a selective thromboxane A₂ synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice. BMC gastroenterology. 2013 Jan; 13(?):21. doi: 10.1186/1471-230x-13-21. [PMID: 23363429]
  • Yukiko Enomoto, Seiji Adachi, Rie Matsushima-Nishiwaki, Tomoaki Doi, Masayuki Niwa, Shigeru Akamatsu, Haruhiko Tokuda, Shinji Ogura, Shinichi Yoshimura, Toru Iwama, Osamu Kozawa. Thromboxane A(2) promotes soluble CD40 ligand release from human platelets. Atherosclerosis. 2010 Apr; 209(2):415-21. doi: 10.1016/j.atherosclerosis.2009.10.024. [PMID: 19932480]
  • Hong-Xia Yao, Li Huang, Li-E Lin, Cong-Ming Wu, Hua Wang, Wen-Ting Chen, Xiang-Jun Fu, Yi-Peng Ding. [The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia]. Zhonghua yi xue za zhi. 2010 Jan; 90(4):253-5. doi: . [PMID: 20356540]
  • Yukihiro Yokoyama, Toru Kawai, Satoru Kawai, Tomomi Kitagawa, Katsutaka Watanabe, Kiyotaka Kawai, Masato Nagino. Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to promote hepatic injury. Shock (Augusta, Ga.). 2008 Jun; 29(6):688-91. doi: 10.1097/shk.0b013e31815812ff. [PMID: 17885643]
  • Hong Wu, Weijiang Yu, Lijun Huang, Jing Wang, Xiaobo Tang, Wei Yang, Yan Liu, Huiyan Yu, Daling Zhu. Effect of sodium ozagrel on the activity of rat CYP2D6. European journal of pharmacology. 2007 Nov; 573(1-3):55-9. doi: 10.1016/j.ejphar.2007.06.055. [PMID: 17651725]
  • Makoto Motoyoshi, Masanori Sugiyama, Yutaka Atomi, Wataru Kimura, Hirokazu Nagawa. Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2. Journal of gastroenterology. 2006 Nov; 41(11):1094-8. doi: 10.1007/s00535-006-1892-0. [PMID: 17160520]
  • Yoichi Ishitsuka, Hiroshi Moriuchi, Keita Hatamoto, Changqing Yang, Junko Takase, Saeid Golbidi, Mitsuru Irikura, Tetsumi Irie. Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. The Journal of pharmacy and pharmacology. 2004 Apr; 56(4):513-20. doi: 10.1211/0022357023150. [PMID: 15099446]
  • Katsuya Sasaki, Hidenori Miyake, Takafumi Kinoshita, Shizuo Ikeyama, Seiki Tashiro. Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation. The journal of medical investigation : JMI. 2004 Feb; 51(1-2):76-83. doi: 10.2152/jmi.51.76. [PMID: 15000260]
  • Hiroyuki Katagiri, Yoshiya Ito, Ken-ichiro Ishii, Izumi Hayashi, Makoto Suematsu, Shohei Yamashina, Takahiko Murata, Shuh Narumiya, Akira Kakita, Masataka Majima. Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice. Hepatology (Baltimore, Md.). 2004 Jan; 39(1):139-50. doi: 10.1002/hep.20000. [PMID: 14752832]
  • Y Ito, H Katagiri, K Ishii, A Kakita, I Hayashi, M Majima. Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes. 2003 Sep; 35(5):408-16. doi: 10.1159/000072174. [PMID: 12928598]
  • Michiaki Okumura, Masahito Imanishi, Mikio Okamura, Masayuki Hosoi, Noriyuki Okada, Yoshio Konishi, Takashi Morikawa, Katsuyuki Miura, Tatsuya Nakatani, Satoru Fujii. Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats. Life sciences. 2003 May; 72(24):2695-705. doi: 10.1016/s0024-3205(03)00180-2. [PMID: 12679187]
  • Yasuko Karasawa, Takehiko Hitomi, Hiroko Komiyama, Yoshihiko Isobe, Tsunefumi Kobayashi, Shigeru Yoshida, Shiro Nakaike, Hiroaki Araki. Effect of TTC-909 in a middle cerebral artery thrombosis model in stroke-prone spontaneously hypertensive rats. European journal of pharmacology. 2002 Aug; 449(1-2):127-133. doi: 10.1016/s0014-2999(02)01945-3. [PMID: 12163116]
  • Roberta Vezza, Anna Maria Mezzasoma, Gigliola Venditti, Paolo Gresele. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thrombosis and haemostasis. 2002 Jan; 87(1):114-21. doi: 10.1055/s-0037-1612953. [PMID: 11848439]
  • S Satoh, T Utsunomiya, K Tsurui, T Kobayashi, I Ikegaki, Y Sasaki, T Asano. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life sciences. 2001 Aug; 69(12):1441-53. doi: 10.1016/s0024-3205(01)01229-2. [PMID: 11531167]
  • Y Yoshimi, M Fujimura, S Myou, H Tachibana, T Hirose. Effect of thromboxane A2 (TXA2) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs. Prostaglandins & other lipid mediators. 2001 May; 65(1):1-9. doi: 10.1016/s0090-6980(01)00099-5. [PMID: 11352222]
  • M S Zhou, H Kosaka, R X Tian, Y Abe, Q H Chen, H Yoneyama, A Yamamoto, L Zhang. L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. Journal of hypertension. 2001 Mar; 19(3):421-9. doi: 10.1097/00004872-200103000-00010. [PMID: 11288812]
  • T Mizutani, S Takahashi, S Kihara, H Toyooka. Effects of a thromboxane receptor antagonist (NT-126) and a thromboxane synthase inhibitor (OKY-O46) on protamine-induced circulatory changes in dogs. Journal of cardiothoracic and vascular anesthesia. 2000 Dec; 14(6):687-92. doi: 10.1053/jcan.2000.18449. [PMID: 11139110]
  • N Takahashi, Y Ishibashi, Y Murakami, H Shimizu, Y Ohta, T Asanuma, H Katoh, K Sano, T Shimada. Beneficial effect of combination therapy with ozagrel and pranlukast in exercise-induced asthma demonstrated by krypton-81 m ventilation scintigraphy--a case report. Annals of the Academy of Medicine, Singapore. 2000 Nov; 29(6):766-9. doi: NULL. [PMID: 11269987]
  • T Ogiso, K Koike, M Iwaki, T Tanino, G Tanabe, O Muraoka. Percutaneous penetration of ozagrel and the enhancement produced by saturated fatty acids. Biological & pharmaceutical bulletin. 2000 Jul; 23(7):844-9. doi: 10.1248/bpb.23.844. [PMID: 10919364]
  • P J Garvin, M L Niehoff, S M Robinson. Effects of tetrodotoxin and OKY-046 in renal ischemia reperfusion. The Journal of surgical research. 1999 Aug; 85(2):273-8. doi: 10.1006/jsre.1999.5685. [PMID: 10423329]
  • K Uriu, K Kaizu, Y L Qie, K Kai, S Eto. Effect of acute thromboxane A2 inhibition on the renal hemodynamics in a spontaneously non-insulin-dependent diabetic rat, Otsuka Long-Evans Tokushima Fatty rat. Journal of diabetes and its complications. 1999 Jul; 13(4):182-6. doi: 10.1016/s1056-8727(99)00041-0. [PMID: 10616856]
  • M Hanaoka, K Kubo, T Hayano, T Koizumi, T Kobayashi. Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade. European journal of pharmacology. 1999 Apr; 370(2):145-51. doi: 10.1016/s0014-2999(99)00107-7. [PMID: 10323263]
  • M Takami, W Tsukada. Effect of DP-1904, a thromboxane synthetase inhibitor, on antigen- and spasmogen-induced bronchoconstriction in rodents. European journal of pharmacology. 1999 Feb; 366(2-3):253-9. doi: 10.1016/s0014-2999(98)00931-5. [PMID: 10082207]
  • H Seki, K Kuromaki, S Takeda, K Kinoshita, K Satoh. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertension in pregnancy. 1999; 18(2):157-64. doi: 10.3109/10641959909023075. [PMID: 10476617]
  • Y Sugawara, Y Harihara, T Takayama, M Makuuchi. Suppression of cytokine production by thromboxane A2 inhibitor in liver ischemia. Hepato-gastroenterology. 1998 Sep; 45(23):1781-6. doi: NULL. [PMID: 9840148]
  • T Iida, H Yokoi, Y Kawarada. The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats. Pancreas. 1998 Aug; 17(2):140-7. doi: 10.1097/00006676-199808000-00005. [PMID: 9700944]
  • H Kunitoh, K Watanabe, A Nagatomo, H Okamoto, T Nakagawa. A double-blind, placebo-controlled trial of the thromboxane synthetase blocker OKY-046 on bronchial hypersensitivity in bronchial asthma patients. The Journal of asthma : official journal of the Association for the Care of Asthma. 1998; 35(4):355-60. doi: 10.3109/02770909809075668. [PMID: 9669829]
  • Y Soejima, K Yanaga, T Nisizaki, T Yoshizumi, H Uchiyama, K Sugimachi. Effect of thromboxane synthetase inhibitor on non-heart-beating donors in rat orthotopic liver transplantation. Surgery. 1998 Jan; 123(1):67-72. doi: 10.1016/s0039-6060(98)70230-2. [PMID: 9457225]
  • T Nagata, Y Uehara, K Hara, K Igarashi, H Hazama, T Hisada, K Kimura, A Goto, M Omata. Thromboxane inhibition and monocrotaline-induced pulmonary hypertension in rats. Respirology (Carlton, Vic.). 1997 Dec; 2(4):283-9. doi: 10.1111/j.1440-1843.1997.tb00090.x. [PMID: 9525298]
  • T Ogiso, M Iwaki, Y Hara, T Tanino. Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations. Journal of pharmaceutical sciences. 1997 Oct; 86(10):1111-4. doi: 10.1021/js970013j. [PMID: 9344166]
  • T Matsumata, K Yamamoto, K Shirabe, M Shimada, K Sugimachi, F Takesue, Y Muto, T Ikeda. Urinary excretion of prostaglandins and renal function after hepatic resection. Hepato-gastroenterology. 1997 May; 44(15):774-8. doi: NULL. [PMID: 9222688]
  • A Okazawa, I Kawikova, Z H Cui, B E Skoogh, J Lötvall. 8-Epi-PGF2alpha induces airflow obstruction and airway plasma exudation in vivo. American journal of respiratory and critical care medicine. 1997 Feb; 155(2):436-41. doi: 10.1164/ajrccm.155.2.9032175. [PMID: 9032175]
  • S Takada, A Numabe, N Hirawa, S Yagi, Y Uehara. Thromboxane inhibition potentiates antihypertensive effects of alpha 1 adrenoceptor antagonists in the rat. Prostaglandins, leukotrienes, and essential fatty acids. 1997 Feb; 56(2):127-34. doi: 10.1016/s0952-3278(97)90509-3. [PMID: 9051722]
  • M Tanaka, M Natori, H Ishimoto, K Miyakoshi, T Miyazaki, T Kobayashi, Y Yoshimura. Effects of a thromboxane synthetase inhibitor (OKY-046) in an ischemia-reperfusion model of intrauterine growth retardation in Sprague-Dawley rats. Biology of the neonate. 1997; 72(3):181-6. doi: 10.1159/000244482. [PMID: 9303217]
  • Y J Kim, Y H Park, H K Moon. Reduction of chronic ciclosporin nephrotoxicity by thromboxane synthase inhibition with OKY-046. Kidney & blood pressure research. 1997; 20(1):38-43. doi: 10.1159/000174109. [PMID: 9192909]
  • K Matsumoto, H Aizawa, H Inoue, S Takata, M Shigyo, N Hara. Role of thromboxane-A2 and cholinergic mechanisms in bronchoconstriction induced by cigarette smoke in guinea-pigs. The European respiratory journal. 1996 Dec; 9(12):2468-73. doi: 10.1183/09031936.96.09122468. [PMID: 8980955]
  • T Nagao, T Nagamatsu, Y Suzuki. Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats. European journal of pharmacology. 1996 Nov; 316(1):73-80. doi: 10.1016/s0014-2999(96)00662-0. [PMID: 8982653]
  • S Matsumoto, Y Kuroda, H Fujita, Y Tanioka, T Sakai, M Hamano, Y Kim, Y Suzuki, Y Ku, Y Saitoh. Extending the margin of safety of preservation period for resuscitation of ischemically damaged pancreas during preservation using the two-layer (University of Wisconsin solution/perfluorochemical) method at 20 degrees C with thromboxane A2 synthesis inhibitor OKY046. Transplantation. 1996 Oct; 62(7):879-83. doi: 10.1097/00007890-199610150-00001. [PMID: 8878377]
  • N Papanikolaou, I Darlametsos, G Tsipas, P Morphake, S Bokas, G Gkikas, A Hornych, J Bariety, E L Gkika, I Karageorgou, K Patsialos. Effects of OKY-046 and nifedipine in cyclosporine-induced renal dysfunction in rats. Prostaglandins, leukotrienes, and essential fatty acids. 1996 Oct; 55(4):249-56. doi: 10.1016/s0952-3278(96)90005-8. [PMID: 8951993]
  • P J Garvin, M L Niehoff, S M Robinson, T Heisler, L Salinas-Madrigal, J Contis, H Solomon. Evaluation of the thromboxane A2 synthetase inhibitor OKY-046 in a warm ischemia-reperfusion rat model. Transplantation. 1996 May; 61(10):1429-34. doi: 10.1097/00007890-199605270-00001. [PMID: 8633364]
  • K Shirabe, K Takenaka, K Yamamoto, M Kitamura, H Itasaka, T Matsumata, M Shimada, K Sugimachi. The role of prostanoid in hepatic damage during hepatectomy. Hepato-gastroenterology. 1996 May; 43(9):596-601. doi: NULL. [PMID: 8799402]
  • K Shirabe, S Kin, Y Shinagawa, S Chen, W D Payne, K Sugimachi. Inhibition of thromboxane A2 activity during warm ischemia of the liver. The Journal of surgical research. 1996 Feb; 61(1):103-7. doi: 10.1006/jsre.1996.0088. [PMID: 8769950]
  • S Kin, K Gu, H Nagami, Y Saitoh, K Nakayama, K Tamura, E Stephanian, D Sutherland. Organ specificity of pancreas preservation compared with kidney and heart preservation. Transplantation proceedings. 1996 Feb; 28(1):335-6. doi: NULL. [PMID: 8644248]
  • I Yokoyama, T Kobayashi, M Negita, S Hayashi, M Yasutomi, A Katayama, K Uchida, H Takagi. Liberation of vasoactive substances and its prevention with thromboxane A2 synthase inhibitor in pig liver transplantation. Transplant international : official journal of the European Society for Organ Transplantation. 1996; 9(1):76-81. doi: 10.1007/bf00336816. [PMID: 8748415]
  • I Yokoyama, M Negita, T Kobayashi, S Hayashi, T Hachisuka, E Sato, A Orihara, K Uchida, H Takagi. Beneficial effect of donor pretreatment with thromboxane A2 synthase inhibitor on the graft survival in pig liver transplantation. The Journal of surgical research. 1996 Jan; 60(1):232-8. doi: 10.1006/jsre.1996.0036. [PMID: 8592420]
  • N X Zheng, H Sato, I Adachi, I Kanamoto, I Horikoshi. Pharmacokinetic and pharmacodynamic studies of a thromboxane synthetase inhibitor, ozagrel, in rabbits. Biological & pharmaceutical bulletin. 1995 Dec; 18(12):1738-43. doi: 10.1248/bpb.18.1738. [PMID: 8787798]
  • T Gomi, T Ikeda, Y Sasaki, T Kosugi, Y Shibuya, J Sakurai. Protective effect of thromboxane synthetase inhibitor on hypertensive renal damage in Dahl salt-sensitive rats. Clinical and experimental pharmacology & physiology. Supplement. 1995 Dec; 22(1):S371-3. doi: 10.1111/j.1440-1681.1995.tb02959.x. [PMID: 9072433]
  • A Kato, A Hishida, T Nakajima. Role of thromboxane A2 and prostacyclin in uninephrectomy-induced attenuation of ischemic renal injury. Kidney international. 1995 Nov; 48(5):1577-83. doi: 10.1038/ki.1995.450. [PMID: 8544417]
  • T Horiguchi, K Enzan, H Mitsuhata, M Murata, M Suzuki. Heparin-protamine complexes cause pulmonary hypertension in goats. Anesthesiology. 1995 Oct; 83(4):786-91. doi: 10.1097/00000542-199510000-00018. [PMID: 7574058]
  • K Kurashima, M Fujimura, Y Hoyano, K Takemura, T Matsuda. Effect of thromboxane A2 synthetase inhibitor, OKY-046, on sputum in chronic bronchitis and diffuse panbronchiolitis. The European respiratory journal. 1995 Oct; 8(10):1705-11. doi: 10.1183/09031936.95.08101705. [PMID: 8586126]
  • F Umeda, T Kuroki, H Nawata. Prostaglandins and diabetic nephropathy. Journal of diabetes and its complications. 1995 Oct; 9(4):334-6. doi: 10.1016/1056-8727(95)80035-d. [PMID: 8573760]
  • H Seki, K Kuromaki, S Takeda, K Kinoshita, K Satoh. The possibility of clinical application of the thromboxane A2 synthase inhibitor, ozagrel, for the treatment and prevention of preeclampsia: a preliminary report. Journal of obstetrics and gynaecology (Tokyo, Japan). 1995 Aug; 21(4):357-65. doi: 10.1111/j.1447-0756.1995.tb01023.x. [PMID: 8775905]
  • I Yokoyama, S Hayashi, T Kobayashi, M Negita, M Yasutomi, K Uchida, H Takagi. Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie. 1995; 195(4):209-15. doi: 10.1007/bf02576790. [PMID: 8525071]
  • K Inoue, K Hamada, F Ueda, Y Shibata, K Kimura. Effect of anti-inflammatory agent etodolac on antigen-induced contractions of the trachea and lung parenchyma of guinea pigs. Prostaglandins, leukotrienes, and essential fatty acids. 1994 Dec; 51(6):451-5. doi: 10.1016/0952-3278(94)90064-7. [PMID: 7708811]
  • K Higo, A Karasawa. Effects of a thromboxane A2-receptor antagonist, a thromboxane synthetase inhibitor and aspirin on prostaglandin I2 production in endothelium-intact and -injured aorta of guinea pigs. Japanese journal of pharmacology. 1994 Dec; 66(4):471-9. doi: 10.1254/jjp.66.471. [PMID: 7723224]
  • P Cozzi, A Giordani, M Menichincheri, A Pillan, V Pinciroli, A Rossi, R Tonani, D Volpi, M Tamburin, R Ferrario. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids. Journal of medicinal chemistry. 1994 Oct; 37(21):3588-604. doi: 10.1021/jm00047a016. [PMID: 7932586]
  • N Yoshida, H Suguro, N Hashimoto, T Majima, M Yamaguchi, T Horie. [Effect of combination therapy with disodium cromoglycate (DSCG) and Ozagrel on non-atopic asthmatics]. Arerugi = [Allergy]. 1994 Oct; 43(10):1262-9. doi: NULL. [PMID: 7826222]
  • T Nagao, M Ito, T Nagamatsu, Y Suzuki. Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats. European journal of pharmacology. 1994 Jul; 259(3):233-42. doi: 10.1016/0014-2999(94)90649-1. [PMID: 7982449]
  • Y Tajiri, F Umeda, T Inoguchi, H Nawata. Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat. Journal of diabetes and its complications. 1994 Apr; 8(2):126-32. doi: 10.1016/1056-8727(94)90062-0. [PMID: 8061349]
  • K Uriu, K Kaizu, O Hashimoto, N Komine, S Etoh. Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats. Kidney international. 1994 Mar; 45(3):794-802. doi: 10.1038/ki.1994.105. [PMID: 8196281]
  • N X Zheng, I Adachi, I Horikoshi, I Kanamoto. Rectal absorption of ozagrel from suppositories in rabbits. Biological & pharmaceutical bulletin. 1994 Feb; 17(2):302-5. doi: 10.1248/bpb.17.302. [PMID: 8205130]
  • M Iwata. Pathophysiology of dogs after 84\% hepatectomy with emphasis on prostaglandin metabolites and the effect of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analog. Surgery today. 1994; 24(12):1056-67. doi: 10.1007/bf01367456. [PMID: 7780227]
  • H Isozaki, K Okajima, H Hara, M Kobayashi. The protective effect of thromboxane A2 synthetase inhibitor against ischemic liver injury. Surgery today. 1994; 24(5):435-40. doi: 10.1007/bf01427037. [PMID: 8054815]
  • H Arakawa, J Lötvall, I Kawikova, C G Löfdahl, B E Skoogh. Leukotriene D4- and prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: role of thromboxane and its receptor. British journal of pharmacology. 1993 Sep; 110(1):127-32. doi: 10.1111/j.1476-5381.1993.tb13781.x. [PMID: 8220872]
  • H Kaneto, J Morrissey, S Klahr. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney international. 1993 Aug; 44(2):313-21. doi: 10.1038/ki.1993.246. [PMID: 8377375]
  • H Arakawa, I Kawikova, B E Skoogh, J Hayes, A Morikawa, C G Löfdahl, J Lötvall. Role of arachidonic acid metabolites in airway responses induced by trimellitic anhydride in actively sensitized guinea pigs. The American review of respiratory disease. 1993 May; 147(5):1116-21. doi: 10.1164/ajrccm/147.5.1116. [PMID: 8484619]
  • S Teraoka, K Takahashi, H Toma, K Ota. Controlled prospective study of treatment for chronic rejection after kidney transplantation by thromboxane synthetase inhibitor. Transplantation proceedings. 1993 Apr; 25(2):2085-6. doi: NULL. [PMID: 8470279]
  • H Morio, A Hirai, T Terano, Y Tamura, S Yoshida. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects. Thrombosis and haemostasis. 1993 Mar; 69(3):276-81. doi: 10.1055/s-0038-1651595. [PMID: 8470052]
  • S Suzuki, T Tanita, H Kubo, Y Ashino, M Chida, K Koike, S Fujimura. Stimulation of pulmonary intravascular macrophages increases microvascular permeability in awake sheep. The Tohoku journal of experimental medicine. 1993 Feb; 169(2):121-30. doi: 10.1620/tjem.169.121. [PMID: 8236243]
  • S Kin, E Stephanian, P Gores, A Moss, Y Shinagawa, B Barrou, R Gruessner, K Tamura, D E Sutherland. Effect of thromboxane A2 synthesis inhibitor OKY046 on canine pancreas and kidney preservation. Transplantation proceedings. 1993 Feb; 25(1 Pt 2):1627-8. doi: NULL. [PMID: 8442215]
  • H Arakawa, I Kawikova, C G Löfdahl, J Lötvall. Bradykinin-induced airway responses in guinea pig: effects of inhibition of cyclooxygenase and thromboxane synthetase. European journal of pharmacology. 1992 Dec; 229(2-3):131-6. doi: 10.1016/0014-2999(92)90546-g. [PMID: 1490516]
  • A Szczeklik, M Krzanowski, P Góra, J Radwan. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992 Oct; 80(8):2006-11. doi: NULL. [PMID: 1391958]
  • W Wu, P H Halebian, R J Hariri, S X Cabrales, G T Shires, P S Barie. Differential effects of cyclo-oxygenase and thromboxane synthetase inhibition on ventilation-perfusion relationships in acid aspiration-induced acute lung injury. The Journal of trauma. 1992 Oct; 33(4):561-7. doi: 10.1097/00005373-199210000-00012. [PMID: 1433403]
  • G Redl, L Woodson, L D Traber, C S Rogers, S Abdi, J T Flynn, D N Herndon, D L Traber. Mechanism of immunoreactive atrial natriuretic factor release in an ovine model of endotoxemia. Circulatory shock. 1992 Sep; 38(1):34-41. doi: NULL. [PMID: 1394862]
  • T Koizumi, K Kubo, T Kobayashi, M Sekiguchi. Effects of thromboxane synthase inhibition on tumor necrosis factor-induced lung injury in sheep. Journal of applied physiology (Bethesda, Md. : 1985). 1992 Aug; 73(2):618-24. doi: 10.1152/jappl.1992.73.2.618. [PMID: 1399989]
  • S Kin, E Stephanian, P Gores, K Shirabe, T Tanaka, A Salazar, K Brayman, R Gruessner, D E Sutherland. Successful 96-Hr cold-storage preservation of canine pancreas with UW solution containing the thromboxane A2 synthesis inhibitor OKY046. The Journal of surgical research. 1992 Jun; 52(6):577-82. doi: 10.1016/0022-4804(92)90132-j. [PMID: 1528034]
  • M G Sirois, J G Filep, A Rousseau, A Fournier, G E Plante, P Sirois. Endothelin-1 enhances vascular permeability in conscious rats: role of thromboxane A2. European journal of pharmacology. 1992 Apr; 214(2-3):119-25. doi: 10.1016/0014-2999(92)90108-g. [PMID: 1516634]
  • T Michibayashi. Vaso-contractile responsiveness of perfused arterial segments to platelet-derived thromboxane A2. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi. 1992 Feb; 28(1):25-33. doi: 10.1540/jsmr.28.25. [PMID: 1392129]
  • R Tokyay, H M Loick, D L Traber, J P Heggers, D N Herndon. Effects of thromboxane synthetase inhibition on postburn mesenteric vascular resistance and the rate of bacterial translocation in a chronic porcine model. Surgery, gynecology & obstetrics. 1992 Feb; 174(2):125-32. doi: NULL. [PMID: 1734570]
  • N Papanikolaou, G Peros, P Morphake, G Gkikas, D Maraghianne, G Tsipas, K Kostopoulos, C Arambatze, E L Gkika, J Bariety. Does gentamicin induce acute renal failure by increasing renal TXA2 synthesis in rats?. Prostaglandins, leukotrienes, and essential fatty acids. 1992 Feb; 45(2):131-6. doi: 10.1016/0952-3278(92)90229-c. [PMID: 1561232]
  • K Yamada, Y Sugisaki, S Suzuki, M Akimoto, H Amemiya, N Yamanaka. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of superoxide dismutase and OKY-046 on THEM: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. Transplant international : official journal of the European Society for Organ Transplantation. 1992; 5 Suppl 1(?):S564-7. doi: 10.1007/978-3-642-77423-2_166. [PMID: 14621878]
  • H Ushijima, M Ito, T Yoshimura, K Mabe, H Okamura. Effects of a thromboxane synthetase inhibitor (OKY-046) on vascular reactivity to angiotensin II after stricture of the abdominal aorta in pregnant rabbits. Artery. 1992; 19(2):63-75. doi: NULL. [PMID: 1580798]
  • G Redl, S Abdi, L D Traber, R J Nichols, J T Flynn, D N Herndon, D L Traber. Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep. Critical care medicine. 1991 Oct; 19(10):1294-302. doi: 10.1097/00003246-199110000-00012. [PMID: 1914487]
  • A A Reyes, S Klahr. Role of platelet-activating factor in renal function in normal rats and rats with bilateral ureteral obstruction. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 1991 Oct; 198(1):572-8. doi: 10.3181/00379727-198-43291. [PMID: 1891471]
  • K P Harris, H Yanagisawa, G F Schreiner, S Klahr. Evidence for two distinct and functionally important sites of enhanced thromboxane production after bilateral ureteral obstruction in the rat. Clinical science (London, England : 1979). 1991 Aug; 81(2):209-13. doi: 10.1042/cs0810209. [PMID: 1653665]
  • M Yokota, E Tani, T Fukumori, Y Maeda, I Yamaura. Effects of subarachnoid hemorrhage and a thromboxane A2 synthetase inhibitor on intracranial prostaglandins. Surgical neurology. 1991 May; 35(5):345-9. doi: 10.1016/0090-3019(91)90042-8. [PMID: 2028380]
  • F Asai, T Ito, S Ushiyama, K Matsuda, T Oshima. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Arzneimittel-Forschung. 1991 May; 41(5):506-10. doi: NULL. [PMID: 1898421]
  • G Goldman, R Welbourn, J M Klausner, C R Valeri, D Shepro, H B Hechtman. Thromboxane mediates diapedesis after ischemia by activation of neutrophil adhesion receptors interacting with basally expressed intercellular adhesion molecule-1. Circulation research. 1991 Apr; 68(4):1013-9. doi: 10.1161/01.res.68.4.1013. [PMID: 1672629]
  • N J Davenport, R E Goldstein, G Z Feuerstein. In vivo enhancement of platelet activating factor-induced prostacyclin production by OKY-046, a selective inhibitor of thromboxane A2 synthase. Journal of cardiovascular pharmacology. 1991 Apr; 17(4):641-6. doi: 10.1097/00005344-199104000-00018. [PMID: 1711633]
  • R A Cambria, R J Anderson, G Dikdan, T W Lysz, I I Hobson RW. Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia. The American surgeon. 1991 Feb; 57(2):76-9. doi: NULL. [PMID: 1847027]
  • G Redl. [Right heart function and endotoxemia in animals]. Wiener klinische Wochenschrift. Supplementum. 1991; 188(?):1-20. doi: NULL. [PMID: 1833887]
  • T Osanai, T Kikuchi, Y Yokono, H Matsumura, O Minami, R Akiba, H Eidoh, A Konta, T Kanazawa, K Onodera. Role of renomedullary thromboxane A2 in development of doca-salt hypertension. Clinical and experimental hypertension. Part A, Theory and practice. 1991; 13(2):159-88. doi: 10.3109/10641969109042057. [PMID: 2065462]
  • I Ono, T Ohura, M Murazumi, R Sakamura, S Chiba. A study on the effectiveness of a thromboxane synthetase inhibitor (OKY-046) in increasing the survival length of skin flaps. Plastic and reconstructive surgery. 1990 Dec; 86(6):1164-73. doi: 10.1097/00006534-199012000-00021. [PMID: 2147062]
  • Y Tajiri, T Inoguchi, F Umeda, H Nawata. Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy. Diabetes research and clinical practice. 1990 Nov; 10(3):231-9. doi: 10.1016/0168-8227(90)90066-3. [PMID: 2073870]